Jasper reported a net loss of $9.1 million and $75.8 million, or basic and diluted net loss per share attributable to common stockholders of $0.32 and $3.95, for the three months and year ended ...

Alongside the approval of Ponlimsi, the FDA is reviewing a BLA for TEV-45779, a biosimilar candidate for Xolair, covering all ...

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving ...

Adults with moderate to severe hidradenitis suppurativa experienced substantial long-term symptom relief and quality of life ...

The trial will examine the efficacy, safety, and pharmacodynamics of S-606001 SRT used with ERT in confirmed LOPD adults.

Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH SAN FRANCISCO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.

Safety and efficacy of pasritamig (PAS) + docetaxel (DOCE) in participants with metastatic castration-resistant prostate cancer (mcrPc): Initial results of a phase 1b study. This is an ASCO Meeting ...

Kali Therapeutics, a biotechnology company focused on the discovery and development of next-generation biologics, today announced that they have entered into a license agreement with Sanofi for a ...

I was reminded of the issue recently when a physician colleague of mine treated an elderly man who presented with signs and ...

The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution ...

Thank you, operator. Joining us on the call today from Rani Therapeutics are Chief Executive Officer, Talat Imran; and Chief Financial Officer, Svai Sanford. Earlier today, Rani released financial ...

First Patient Dosed (FPD) in Phase 2a MAINSAIL Trial of NAV-240 in Hidradenitis Suppurativa (HS)Phase 1b Multiple Ascending ...